Status: Recruiting
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.
Participants needed: 66
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Ying LinUpdated: Mar 9, 2023Locations: 1
Eligibility criteria
Histologically documented Her-2 negative [+4]
Patients who are pregnant or lactating at the time of randomization or refuse to... [+6]